Register | Login
Intellectual Property Today
RFC Express - Document Management System
2013 Top Patent Firms
2013 Top Trademark Firms
Current Issue

Advertising Opportunities

Click Here

Email A Friend Back to Archived News

Cytori Patent Allowance Expands Celution® System Protection for Adipose Stem & Regenerative Cell Processing

Thursday, February 05, 2009

San Diego, CA -- Cytori Therapeutics (Nasdaq: CYTX) received a Notice of Allowance from the United States Patent and Trademark Office on a patent application which broadens protection of the Company’s Celution® System. The more than 40 allowed claims create several new layers of protection related to the automated processing of stem and regenerative cells from adipose tissue. Key claims include the following:

  • Alternative Celution System configurations beyond those covered in the Company’s core device patent (U.S. Patent No. 7,390,484);
  • Expanded protection for cosmetic and reconstructive surgery applications; and
  • Technology within the device that optimizes intravascular delivery of adipose derived stem and regenerative cells

Alternative configurations could accelerate processing times, be tailored to smaller volume procedures, or include a desktop version. These claims also expand the array of Celution output compositions protected by Cytori’s intellectual property, so that combinations of cells, matrices, and other additives specific to needs of reconstructive and cosmetic surgery, as well as other applications are protected more broadly. The claims related to intravascular delivery are potentially applicable to a variety of clinical applications for the Celution System output, which include cardiovascular disease, liver disease, and renal failure.

Cytori’s intellectual property portfolio related to the devices, methods and uses of adipose-derived stem and regenerative cells includes nine U.S. and international patents and over 120 applications pending worldwide.

About Cytori

Cytori's (Nasdaq: CYTX) goal is to be the global leader in regenerative medicine. The company is dedicated to providing patients with new options for reconstructive surgery, developing treatments for cardiovascular disease, and banking patients' adult stem and regenerative cells. The Celution® 800 System is being introduced in Europe into the reconstructive surgery market while the Celution® 900 System is being commercialized globally for cryopreserving a patient's own stem and regenerative cells. Clinical trials are ongoing in cardiovascular disease and planned for spinal disc degeneration, gastrointestinal disorders, and other unmet medical needs.

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include our history of operating losses, the need for further financing, regulatory uncertainties regarding the collection and results of, clinical data, dependence on third party performance, and other risks and uncertainties described under the "Risk Factors" in Cytori's Securities and Exchange Commission Filings. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.

Back to Archived News
Looking for...

  © Copyright 2013 Intellectual Property Today
Download Adobe Reader for free